Humacyte, Inc. Accounts Receivable
Humacyte, Inc. (HUMA) had Accounts Receivable of $330.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-08-12
- 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $330.00K.
- 2026-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $434.00K.
- 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $441.00K.
- 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $1.08M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current | Accounts Receivable, after Allowance for Credit Loss, Current as first filed |
|---|---|---|
| 2026-06-30 | $330.00K 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $434.00K 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $441.00K 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $1.08M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $394.00K 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $488.00K 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $0.00 10-K · filed 2026-03-27 | $180.00K 10-Q · filed 2025-05-13 |
| 2023-12-31 | $0.00 10-K · filed 2024-03-28 | |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $31.00K 10-K · filed 2024-03-28 | |
| 2022-09-30 | $31.00K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $1.30M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $233.00K 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $176.00K 10-K · filed 2023-03-24 | |
| 2021-09-30 | $240.00K 10-Q · filed 2021-11-15 | |
| 2020-12-31 | $113.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |